GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aprogen Biologics Inc (XKRX:003060) » Definitions » Debt-to-Revenue

Aprogen Biologics (XKRX:003060) Debt-to-Revenue : 1.75 (As of Dec. 2024)


View and export this data going back to 1984. Start your Free Trial

What is Aprogen Biologics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Aprogen Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩105,821 Mil. Aprogen Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩48,197 Mil. Aprogen Biologics's annualized Revenue for the quarter that ended in Dec. 2024 was ₩88,196 Mil. Aprogen Biologics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 1.75.


Aprogen Biologics Debt-to-Revenue Historical Data

The historical data trend for Aprogen Biologics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprogen Biologics Debt-to-Revenue Chart

Aprogen Biologics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.04 2.07 2.07 2.29

Aprogen Biologics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.99 2.95 2.70 1.84 1.75

Competitive Comparison of Aprogen Biologics's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Aprogen Biologics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aprogen Biologics's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aprogen Biologics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aprogen Biologics's Debt-to-Revenue falls into.


;
;

Aprogen Biologics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Aprogen Biologics's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(105820.538 + 48196.56) / 67378.141
=2.29

Aprogen Biologics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(105820.538 + 48196.56) / 88196.26
=1.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Aprogen Biologics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aprogen Biologics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aprogen Biologics Business Description

Traded in Other Exchanges
N/A
Address
545, Dunchon-daero, Jungwon-gu, Gyeonggi-do, Seongnam-si, KOR
Aprogen Biologics Inc is specialized in manufacturing and selling various pharmaceutical products including amino acid infusion agents and antibiotics.

Aprogen Biologics Headlines

No Headlines